WCLC 2024 is scheduled to take place in San Diego, USA, from September 7 to 10, 2024, local time. Due to highly significant research findings, Hansoh Pharma’s innovator drug, Almonertinib, and the much-anticipated pipeline product, HS-20093, are both included in the “Late Breaking Abstract (LBA)” list, which has been released by the conference. An additional 12 innovative results for Almonertinib have been accepted by this year's conference, covering neoadjuvant therapy, adjuvant therapy, combination chemotherapy, combination radiotherapy, and brain metastasis.

Part 1: Late Breaking Abstract (LBA)

【1.1】 Aumolertinib Maintenance after Chemoradiotherapy in stage Ⅲ Non-Small-Cell Lung Cancer: Interim Results of the phase Ⅲ study (POLESTAR)

Authors: J. Yu, X. Meng, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan/CN

【1.2】 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase Ⅰ Study (ARTEMIS-001)

Author: J. Wang, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing/CN

Part 2: Mini Oral Presentation

【2.1】 Aumolertinib as adjuvant therapy in resectable Ⅰ-Ⅲ EGFR-mutant NSCLC : also effective in patients with high-risk relapse factors

Author: J. Yao，Jilin Province People's Hospital, Changchun/CN

Part 3: Research Design

【3.1】 MRD guiding treatment after Aumolertinib induction therapy for EGFRm+ stage Ⅲ NSCLC in the MDT diagnostic model (APPROACH)

Authors: Q. Zhou，Y-L Wu, MD, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangzhou/CN

【3.2】 Efficacy and safety of Aumolertinib with radiotherapy in the treatment of unresectable locally advanced EGFR-mutant NSCLC: a phase Ⅱ study

Author: X. Meng, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan/CN

Part 4: Research Data

【4.1】 Aumolertinib as neoadjuvant therapy for EGFRm+ NSCLC: a subcohort analysis of PURPOSE trial data updated

Author: W.T. Fang，Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai/CN

【4.2】 Aumolertinib in treatment-naïve EGFR-mutant NSCLC patients with brain metastases: efficacy and safety data from the ARTISTRY

Authors: X. Zhang， H. Wang，The affiliated hospital of Zhengzhou university, Henan Cancer Hospital, Zhengzhou/CN

【4.3】 Aumolertinib with chemotherapy as first-line treatment in patients with EGFR-mutated advanced NSCLC: a real-world study

Authors: J. Xu，R. Guo，The First Affiliated Hospital of Nanjing Medical University, Nanjing/CN

【4.4】 Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage Ⅰ NSCLC with multiple high-risk factors

Author: Q. Wu，the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an/CN

【4.5】 Safety and efficacy of cranial radiotherapy in combination with Aumolertinib in EGFR-mutant NSCLC patients with brain metastases

Author: N. Bi，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Beijing/CN

【4.6】 Adjuvant Aumolertinib in resected stage I EGFR-mutated NSCLC: prospectively evaluating efficacy in residual GGN lesions

Author: C.B. Huang，Tianjin medical university cancer institute & hospital, Tianjin/CN

【4.7】 Adjuvant Aumolertinib in patients with completely resected, stage ⅠA2-ⅢA Non-Small-Cell Lung Cancer with uncommon EGFR mutations

Author: J. Hu，The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou/CN

【4.8】 Efficacy and safety of Aumolertinib in stage ⅠB-ⅢA NSCLC after R0 resection and the correlation between efficacy and postoperative MRD status

Author: S. Yang，The first people's hospital of foshan, foshan/CN

Part 5: Case Series

【5.1】 High-dose Aumolertinib combined intrathecal chemotherapy for the treatment of EGFR-mutated NSCLC with leptomeningeal metastasis

Author: W. Wang, Chongqing University Three Gorges Hospital, Chongqing/CN